Skip to main content

Transplantation unit (Hematology)

There are two types of hematopoietic stem cell transplantation:

  • autotransplantation: autologous transplantation, using stem cells taken from the patient,
  • allotransplantation: allogenic transplantation,  using stem cells taken from a compatible brother or sister (known as a family or related transplant), or the stem cells of a voluntary and anonymous donor (an unrelated allogenic transplant). 

In practice, a transplant that follows a course of chemotherapy (the conditioning) takes place like a blood transfusion, the stem cells themselves lodging in the bone cavities where they multiply and ensure the restoral of the hematological and immune system. 

The first autologous transplantation of stem cells at the Jules Bordet Institute was carried out in 1981, followed by the first allogenic transplantation in 1984. 

Our programme was approved in 2009 by the Joint Accreditation Committee of the ISCT and EBMT or JACIE, recognising it as a centre of excellence for autologous and related and unrelated allogenic stem cell transplantations. 

The programme is growing, given the clear increase in transplant indications. We currently carry out about 35 autotransplants and 35 allotransplants a year. For the allotransplants we have a sterile unit with  6 laminar flow chambers.

Our programme is well supported by several specialists in medicine in addition to the hematologists specialising in transplantations, including infectiologists, intensivists and other specialists who possess the necessary skills to treat our patients. 

Also, in order to provide our patients with the most innovative treatment, the unit is engaged in clinical research
• Academic, in cooperation with the Belgian Hematological Society (BHS),  the EORTC, the LYSA, the IFM and the EBMT
• In cooperation with biotechnology firms for the handling of the graft in the framework of immunomodulation. 

Research projects

Participation aux protocoles cliniques de transplantation de groupes coopératifs académiques

Our team

Head of Department
- Prof Nathalie Meuleman -  Hematologist (Multiple Melomas and Plasmocytary Disorders: Autotransplants)

Head of Transplantation Unit
Prof Philippe Lewalle - Hematologist (Allotransplants)

Heads of the Clinics
- Prof Sebastian Wittnebel - Hematologist (Leukemias, Myelodysplasias and Allotransplants)

- Prof Marie Maerevoet -   Hematologist (Lymphomas and Lymphoproliferative Disorders: Autotransplant

Professor Emeritus
Prof Dominique Bron – Hematologist (Lymphomas and Chronic Lymphoid Leukemias)

Resident doctors 
Dr Chloé Spilleboudt (Allotransplants)
Dr Marie Vercruysen (Autotransplants)
Dr Adriano Salaroli (Allogreffe)
Dr Fabio Andreozzi (Allogreffe)
Dr Fulvio Massaro (Autogreffe)

Qualitician
- Aurélie Timmermans
Sfia Bourdji

Head Nurse
Patrick Crombez

Transplant coordination and health education nurse
- Jaivenois Marie France
- Rezarta Ajazi

Transplant coordinator
- Sandra Michiels

10/02/2022

 Scientific publications

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.

Authors : Zijlstra JM, Follows G, Casasnovas RO, Vermaat JSP, Kalakonda N, Choquet S, Hill B, Thieblemont C, Cavallo F, Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vassilakopoulos TP, Samal P, Ku M, Xu J, Corona K, Chamoun K, Shah J, Canales M, Maerevoet M
Year : 2022
Journal : Cancers (Basel)
Volume : 14

New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.

Authors : Andreozzi F, Massaro F, Wittnebel S, Spilleboudt C, Lewalle P, Salaroli A
Year : 2022
Journal : Int J Mol Sci
Volume : 23

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Authors : Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T, Leleu X
Year : 2022
Journal : Leukemia
Volume : 36
Pages : 881-884

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.

Authors : Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, Van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M
Year : 2022
Journal : Cancer
Volume : 128
Pages : 1004-1014

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Authors : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 3